Treatment options in p53abn/CNH endometrial cancer: approved and in trial
| Mechanism of action | Agents | Status | Trial(s) |
| Anti-PD-1 antibody+multi-kinase inhibitor | Pembrolizumab+lenvatinib | FDA approved | KEYNOTE-775, KEYNOTE-146 |
| Anti-human epidermal growth factor receptor 2 antibody+chemotherapy | Trastuzumab+carboplatin/paclitaxel | Published | NCT01367002 |
| Trastuzumab+pertuzumab + carboplatin/paclitaxel | Not yet recruiting | NRG-GY026 | |
| PARP inhibitor+chemotherapy | Niraparib+carboplatin/paclitaxel | Recruiting | CAN-STAMP |
| PARP inhibitor+chemoradiation | Olaparib+chemoradiation | Recruiting | RAINBO |
| Antibody drug conjugates | Trastuzumab-deruxtecan | Completed | STATICE, |
| Trastuzumab-deruxtecan | Active, not recruiting | DESTINY-Pan Tumor02 | |
| Antibody drug conjugates+PARP inhibitor | Trastuzumab-deruxtecan+olaparib | Recruiting | NCI-2020–07841 |
| WEE1 inhibitor | Adavosertib | Recruiting | 18–316 |
CNH, copy number high; FDA, US Food and Drug Administration; PARP, poly (ADP-ribose) polymerase ; PD-1, programmed cell death protein 1.